** Shares of medtech firm Glaukos Corp GKOS.N rise 3.3% to $158 premarket

** Brokerage Mizuho upgrades rating on GKOS to "outperform" from "neutral", citing its "disruptive potential" in the US glaucoma market

** Also raises PT to $200 from $140; representing a 30.8% upside to the stock's last close

** Brokerage says it believes iDose has a "substantial lead" in the drug-device combo setting and can drive up to $7 in adjusted EPS by 2030

** iDose is a device that helps lower eye pressure in people with glaucoma, a disease that damages the optic nerve, by slowly releasing medicine

** Expects iDose sales to reach over $1 bln by 2029, driven by a "favorable US adoption cycle with expanded coverage over the next several years"

** Says iDose has a unique advantage over competing products, such as Abbvie's ABBV.N Durysta implant, due to its "reservoir design that allows for continuous drug elution up to 3 years"

** GKOS gained 94.6% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))